Determining the Dose of Azathioprine Based on the Lower Limit of Leukocyte Count in Patients with Crohn's Disease

Geom Seog Seo

doi:10.4166/kjg.2013.62.2.83

Journal List > Korean J Gastroenterol > v.62(2) > 1007188

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Seo: Determining the Dose of Azathioprine Based on the Lower Limit of Leukocyte Count in Patients with Crohn's Disease

Editorial

Korean J Gastroenterol 2013;62(2):83-84.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.62.2.83

Determining the Dose of Azathioprine Based on the Lower Limit of Leukocyte Count in Patients with Crohn's Disease

Geom Seog Seo

Department of Internal Medicine, Digestive Disease Research Institute, Wonkwang University College of Medicine, Iksan, Korea

Correspondence to: Geom Seog Seo, Department of Internal Medicine, Digestive Disease Research Institute, Wonkwang University College of Medicine, 460 Iksan-daero, Iksan 570-749, Korea. Tel: +82-63-859-2565, Fax: +82-63-855-2025, E-mail: medsgs@wonkwang.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

How Should Thiopurines Be Dosed in Crohn's Disease? A Novel Strategy of Maximum Dose-titration Based on the Lower Limit of Leukocyte Count and Tolerability

References

1. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000; (2):CD000545.

2. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6-mercap-topurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2013; 4:CD000545.

3. Lee HJ, Yang SK, Kim KJ, et al. The safety and efficacy of azathioprine and 6-mercaptopurine in the treatment of Korean patients with crohn's disease. Intest Res. 2009; 7:22–31.

4. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002; 50:485–489.

5. Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol. 2008; 51:291–297.

6. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease:27 years of experience. Gut. 1993; 34:1081–1085.

7. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989; 111:641–649.

8. Lichtenstein GR. Use of laboratory testing to guide 6-mercapto-purine/azathioprine therapy. Gastroenterology. 2004; 127:1558–1564.

9. Kim WH, Cho JH, Kim TI. Rational dosing of azathioprine and 6-mercaptopurine in inflammatory bowel diseases. Korean J Gastroenterol. 2003; 41:423–437.

10. Hyun KH, Lee SH, Shin JM, et al. Frequency of bone marrow toxicity by using pattern of azathioprine in inflammatory bowel disease patients. Intest Res. 2012; 10:244–250.

11. Kim JH, Cheon JH, Kim TI, Kim WH. A survey of actual clinical practice patterns in the treatment of inflammatory bowel disease in Korea. Intest Res. 2009; 7:79–85.

12. Lim CS, Moon W, Park SJ, et al. How should azathioprine be dosed in Crohn's disease? A novel strategy of maximum dose-ti-tration based on the lower limit of leukocyte count and tolerability. Korean J Gastroenterol. 2013; 62:111–116.

TOOLS

Similar articles